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AIMS
To investigate the range of methods used to validate diagnoses in the General Practice Research Database (GPRD),to summarize ﬁndings and
to assess the quality of these validations.
METHODS
A systematic literature review was performed by searching PubMed and Embase for publications using GPRD data published between 1987
and April 2008.Additional publications were identiﬁed from conference proceedings,back issues of relevant journals,bibliographies of
retrieved publications and relevant websites.Publications that reported attempts to validate disease diagnoses recorded in the GPRD were
included.
RESULTS
We identiﬁed 212 publications,often validating more than one diagnosis.In total,357 validations investigating 183 different diagnoses met our
inclusion criteria.Of these,303 (85%) utilized data from outside the GPRD to validate diagnoses.The remainder utilized only data recorded in
the database.The median proportion of cases with a conﬁrmed diagnosis was 89% (range 24–100%).Details of validation methods and results
were often incomplete.
CONCLUSIONS
A number of methods have been used to assess validity.Overall,estimates of validity were high.However,the quality of reporting of the
validations was often inadequate to permit a clear interpretation.Not all methods provided a quantitative estimate of validity and most
methods considered only the positive predictive value of a set of diagnostic codes in a highly selected group of cases.We make
recommendations for methodology and reporting to strengthen further the use of the GPRD in research.
Introduction
Computerized databases of medical records are increas-
ingly used in biomedical research. The General Practice
Research Database (GPRD) is a primary care database
containing anonymized patient records for about 6% of
the UK population.The GPRD’s strengths as a research tool
include its size,representativeness of patient and practice
characteristics [1],and a virtually complete medical history
of patients due to the recording of referral to secondary
care [2].The GPRD has been widely used for observational
studies, with over 550 studies published to date in peer-
reviewed journals [3].
A typical dataset from the GPRD contains information
onapatient’ssex,age,yearofbirthandregistrationdetails.
Participating general practices are required to record (i)
each episode of illness, or new occurrence of a symptom,
and (ii) all signiﬁcant morbidity events, e.g. all signiﬁcant
clinical contacts, all signiﬁcant diagnoses and abnormal
test results, all referrals to outpatient clinics and hospital
admissions[3].Inordertoentercomputerizedinformation,
the general practitioner (GP) types a descriptive term for
thesymptomordiagnosisandchoosesthemostappropri-
ate entry from a drop-down list of possible choices, with
corresponding Oxford Medical Information Systems
(OXMIS)andReadcodes.Therapeuticinformationincludes
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Authority, with the corresponding date, dosage and
method of administration. Additional information is pro-
vided on vaccinations, weight and blood pressure mea-
surements,laboratory test results and on some aspects of
lifestyle. All information is entered by practice staff and is
anonymized prior to central collection.
ThevalidityofresearchbasedonGPRDdatadependson
the quality and completeness of data recorded. For
example, following the publicity about a possible link
between measles, mumps and rubella vaccination and
autism, studies were undertaken using GPRD [4–6]. The
high validity of a recorded diagnosis of autism demon-
strated in these studies was an important factor in helping
ensure the study ﬁndings were accepted.The GPRD carries
out a series of ongoing checks to ensure that the data are
‘uptostandard’;thiscomprisesassessmentofbothpatient
data (age, gender, registration details and event dates)
and the completeness, continuity and plausibility of elec-
tronic data recording in key areas at the practice level (for
example, ensuring a minimum speciﬁed percentage of
deaths have cause of death recorded, a minimum referral
rate per 100 patients,and a minimum number of prescrip-
tionsperpatientpermonth).PrescriptiondataintheGPRD
are known to be well documented: the GP uses the com-
putertogenerateprescriptionsandtheseareautomatically
recordedinthedatabase.Thetherapyﬁleisthereforevirtu-
ally complete,except for prescriptions issued in secondary
care and for drugs that are purchased over the counter [7].
In contrast,new diagnoses must be manually recorded on
thecomputerandalthoughallsigniﬁcantdiagnosesshould
be included, they may be incomplete. Additionally, condi-
tionsmaybemisdiagnosedormiscodedinGPrecords,e.g.
codes selected mistakenly or tentative diagnoses coded
using‘deﬁnite’clinicalcodes.Toexaminethesepossibilities,
investigators have assessed the validity of certain com-
puterized diagnoses by conducting validation studies.
Speciﬁcvalidationstudieshavesuggestedhighvalidity
of diagnoses recorded in the GPRD,reporting strong mea-
sures of positive predictive value (PPV), sensitivity and
speciﬁcity[8–14].However,therehasnotbeenasystematic
review of all validation studies of diagnoses to assess the
totality of evidence.Here we report a systematic review of
studies that assessed quality of morbidity and mortality
data available in the GPRD.The aims of the review were to
investigate the range of methods used to validate diag-
nosesintheGPRD,summarizetheﬁndingsofthesestudies
and assess the quality of reporting of validation methods
and results.
Methods
Search strategy
We searched PubMed and Embase for publications using
the GPRD data published between 1987 and April 2008.
Bibliographies on the websites of the GPRD (http://
www.gprd.com/bibliography/) and the Boston Colla-
borative Drug Surveillance Program (http://www.
bcdsp.net/publications.html) were scrutinized to identify
additional articles. Selected International Society of
Pharmacoepidemiology conference proceedings, issues
of Health Statistics Quarterly, and back issues of Pharma-
coepidemiology and Drug Safety that were not incorpo-
rated into PubMed were hand-searched.Reference lists of
identiﬁed articles were examined.Our ﬁrst search linked a
comprehensivelistoffreetexttermsandexplodedthesau-
rus terms to identify GPRD publications in which a diag-
nostic validation was reported. This preliminary search
showed that terms indicating case validation were not
mentioned in the title, abstract or keywords in many
published papers. Therefore, we broadened our search
strategy to identify all publications reporting the use of
GPRD data.
Study selection
We examined the full text of all publications identiﬁed via
thesearchstrategythatpossiblyusedGPRDdataandwere
published in English. A publication was considered for
initial inclusion when a set of medical codes for a syn-
drome,disease diagnosis or death,deﬁned by the investi-
gators as a ‘case’, was veriﬁed using one of the methods
summarized in Table 1. Such methods use data either
entirely contained within the database (internal valida-
tions) or from outside the database (external validations).
Inclusion criteria
Publications using methods 1,2,4 and 5 (seeTable 1) were
included only if a quantitative estimate of validity (e.g.
the proportion of cases with a conﬁrmed diagnosis) was
described or could be calculated. Publications using
method 3 were included when results of the sensitivity
analyses were reported. We did not include validations
verifying only the date of diagnosis, idiopathic diagnoses
(e.g.reviewing records of venous thromboembolism cases
toidentifythosewithidiopathicdiseaseratherthanaclear
cause [15]), severity of diagnosis, or studies not validating
diagnoses(e.g.prescriptions,procedures,smoking)orwere
set up to distinguish incident from prevalent diagnoses.
Eligibility was assessed by three reviewers (W.M.S., S.L.T.,
E.H.);all disagreements were resolved after discussion.
Data extraction
Data extraction was conducted by two reviewers (W.M.S.,
E.H.)usingastandardizeddataextractionsheet,andathird
reviewer (A.J.H.) assessed a random sample of 10% of the
articles to verify the extraction process. Data extracted
included the disease validated, the validation method(s)
used and,where appropriate,the proportion of cases with
a conﬁrmed diagnosis.Details regarding the quality of the
validationexerciseincludingGPresponseratestorequests
for information, the number and proportion of total
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viewers and case selection methods were also recorded.
The speciﬁc OXMIS, Read or International Classiﬁcation of
Diseases (ICD) codes used to identify each condition were
not extracted,as describing the validity of a single disease
or group of diseases was not the purpose of this review.
Data analysis
Each validation study was categorized as internal or exter-
nal and then by the validation method used. If a publica-
tion validated more than one diagnosis, each diagnosis
was analysed separately. Also, if a publication used more
thanonemethodtovalidateadiagnosis,eachmethodwas
considered a separate validation.The proportion of cases
with a conﬁrmed diagnosis was calculated overall, by
disease group (categorized by ICD 10 chapter where
possible) and for each validation method. The quality
of reporting was analysed by validation method; the
median or mean value for each data quality variable was
calculated.
Results
We identiﬁed a total of 1515 nonduplicate abstracts from
the PubMed, EMBASE and website searches, of which 806
were deﬁnitely not GPRD studies after reviewing title and
abstract (Figure 1). Reviewing papers and hand-searching
relevant journals and conference proceedings identiﬁed
another 222 publications.After reviewing the full text, we
included 212 of these 931 publications.The main reasons
for exclusion were: no validation of the diagnosis under
investigation (n = 478), data source used was not GPRD
(n = 62), the publication reported a previously published
validation (n = 47), or no diagnosis was investigated (n =
132),e.g.study of prescriptions or procedures.
Fortyofthe212publicationsvalidatedasinglediagno-
sis using a combination of methods. For example, Ruigo-
mez [16] performed three validations of atrial ﬁbrillation:
ﬁrst a manual review of computerized records, then by
a questionnaire to the GP and ﬁnally a comparison of
disease incidence to an external source. Twenty-nine
papers validated more than one diagnosis, e.g. Hollowell
[7] validated allergic rhinitis, diabetes, chicken pox and
asthma by comparing GPRD rates of each with external
sources.
The 212 publications reported 357 validations, verify-
ing 183 different diagnoses (Figure 1).There were 14 pub-
lications where validation was the main focus of the
study. Table 2 shows the frequency of use of the different
validation methods. Eighty-three percent of validations
were external; use of a questionnaire to the GP and/or a
request for copied medical records were the most com-
monly used (160/357, 45%), while a comparison of rates
was carried out in 40% of the 357 validations. Of the 31
validations that used internal methods, a minimum of 24
used a manual review; in the remaining seven it was not
possible to determine whether a manual review of com-
puterized records or a diagnostic algorithm had been
conducted.
Table 1
Methods used in validations of diagnoses in the General Practice Research Database (GPRD)
Method Description Example
Internal 1 Diagnostic algorithm A diagnosis was validated by the presence of codes
indicating speciﬁc symptoms/signs, prescriptions for
disease-speciﬁc drugs and/or conﬁrmatory test results
Andersohn [23] validated acute myocardial infarction by
choosing only cases with codes for troponin tests,
treatment with ﬁbrinolytic drugs, coronary intervention
or a hospital stay of >3 days
2 Manual review of anonymized
free text on computerized
records
The complete computer records (including the anonymized
free text) for individuals with a diagnosis were assessed
for conﬁrmatory evidence of disease status
Yang [15] validated colorectal cancer cases by reviewing
the computerized records to look for clinical events to
conﬁrm the diagnosis
3 Sensitivity analysis In an analytical study, a comparison of the measure of
effect using a broad set of disease/therapeutic codes
with that of a restricted set more likely to represent
true cases
Gupta [26] varied the deﬁnition of multiple sclerosis to
examine how its association with inﬂammatory bowel
disease changed
External 4 Questionnaire to GP A questionnaire investigating various aspects of the
computerized diagnosis was sent to the GP
Garcia Rodriguez [27] validated prostate cancer by
comparing the computerized diagnosis with answers to
a questionnaire ﬁlled by the GP regarding the diagnosis
5 Record request to GP Request to the GP to provide anonymized copies of paper
medical records, hospital discharge summaries or death
certiﬁcates. Obtained copies were examined to validate
the diagnosis, using further diagnostic criteria
Hall [28] requested medical records of lung cancer patients
in order to verify the cancer diagnosis made in the
computerized records
6 Comparison of rates Measures of disease incidence, prevalence or patterns (e.g.
time trends) from GPRD data were compared with a
non-GPRD, UK-based data source
Hollowell [7] compared the incidence of chicken pox,
allergic rhinitis, asthma and diabetes with external rates
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Overall, a high proportion of cases were conﬁrmed for
all diseases with a median of 89% and range 24–100%
(Table 2),i.e.89of100caseswithacomputerizeddiagnosis
were conﬁrmed based on additional internal or external
information.Withineachdiseasecategoryandmethodthe
proportion of cases conﬁrmed varied widely (Table 3) but
the median proportion was >80% for most categories.
Rate comparisons and sensitivity analyses did not
conﬁrm cases individually, but provided additional evi-
dence of a high validity of diagnoses in the GPRD.Disease
incidence and prevalence estimates based on GPRD data
were comparable to other UK population-based sources,
with a few exceptions. For example, the incidence rate of
rheumatoid arthritis (RA) based on GPRD data was 50%
higher than previous estimates, which was attributed to
over-ascertainment of RA by GPs in the GPRD compared
with rheumatologists [17]. Conversely, the prevalence of
musculoskeletaldiseasesintheGPRDwasunderestimated
by the GPRD when compared with other general practice
databases [18].Most sensitivity analyses showed no differ-
ences between measures of effect calculated with broad
1515 non-duplicate abstracts
identified from PubMed, EMBASE,
GPRD and BCDSP
806 abstracts excluded
because they did not use
GPRD as a data source
709 publications retrieved for full
text searching
222 additional publications
identified from reviewing
publications, hand searching ISPE
conference procedures, PDS back
issues, and HSQ issues
212 publications included
357 validations
183 different diagnoses
719 publications excluded
because:
(i) did not use GPRD
(n = 62), (ii) not in English
(n = 2), (iii) did not study a
diagnosis (n = 132), (iv)
described a validation that
was published elsewhere
(n = 47), (v) did not validate
the diagnosis under study
(n = 478)
Internal methods
31 Manual review of
computerized records
or diagnostic algorithm
29 publications
26 different diagnoses
23 Sensitivity
analysis
22 publications
18 different
diagnoses
160 Additional
information from GP
123 publications
106 different
diagnoses
143 Comparison
of rates
84  publications
99 different
diagnoses
43 Questionnaire
to GP
36 publications
31 different
diagnoses
39 Questionnaire
and record
request to GP
20 publications
36 different
diagnoses
78 Record request
ro GP
68 publications
53 different
diagnoses
External methods
Figure 1
Stream diagram of article search, retrieval and review process. GPRD, General Practice Research Database; BCDSP, Boston Collaborative Drug Surveillance
Program;ISPE,International Society of Pharmacoepidemiology;PDS,Pharmacoepidemiology Drug Safety;HSQ,Health Statistics Quarterly
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suggesting that the majority of cases included in the origi-
nal deﬁnition were veriﬁed by the stricter criteria.
Quality of reporting
The medical codes used to deﬁne cases were seldom
reported in papers, although some researchers indicated
that they would make code lists available. Occasionally,
medical codes from the GPRD coding system (OXMIS and
Read codes) were mapped onto ICD codes, but no details
were given about which OXMIS/Read codes corresponded
to speciﬁc ICD codes.
Table 4 shows the results of the data quality assess-
ment. The number of cases undergoing validation varied
according to the method used (Table 4, column B). Infor-
mation requests typically validated fewer cases, but
numbers were highly variable [range 1–3010 (median 100
cases)]. Comparisons of incidence or prevalence were
oftenbasedonlargenumbersofcasesandwithacommon
disease reached as many as 200 000 [19],with a median of
1984 cases for this method.
The proportion of identiﬁed cases undergoing valida-
tion also varied (Table 4, column C). Some investigators
reported validating 100% of identiﬁed cases. However,
these were often a very small and highly selected group of
cases chosen using strict inclusion criteria. Many valida-
tions included only cases that (i) already had some sup-
porting evidence in their records or (ii) were restricted,e.g.
by age,presence of comorbid conditions or by having had
speciﬁc therapies. Publications with broader inclusion cri-
teria validated far fewer of the total cases and in several
publications the proportion validated was <0.5%. Few
of these studies reported how they sampled cases for
validation from all eligible cases.
Eighty-four percent (134) of 160 validations requesting
additional information from GPs reported GP response
rates;55–100% (median 90%) of requests were met by GPs
(Table 4, column D). In general, details were not provided
on how many patient records were unavailable (e.g.due to
patient transfer or death). Similarly, most validations did
not report blinding of reviewers during review of patient
records.
Discussion
This review identiﬁed 212 publications in which 183 differ-
ent diagnoses were validated. Given the breadth of our
search strategy,we feel that we are likely to have captured
the majority of validations of GPRD diagnostic data pub-
lished in the speciﬁed time period.
The majority of validations were external, and most
frequently were requests to GPs to provide additional
information. Relatively few publications documented use
of internal validations. Overall, quantitative estimates of
validity were high (median 89% of cases conﬁrmed) and
qualitative evidence from external rate comparisons and
sensitivity analyses supported the validity of diagnoses.
However, we are reluctant to draw conclusions regarding
the overall validity of diagnoses in the database, for
three reasons. First, despite their strengths, the methods
presented here have limitations: questionnaires to GPs,
record requests, algorithms and manual reviews predo-
minantly examine PPV, whereas sensitivity analyses and
comparisons of rates cannot provide quantitative esti-
mates of validity. Even where quantitative validations are
carried out, it may only be possible to categorize some
coded cases as‘possible cases’based on the extra informa-
tion given in the case notes.Second,the quality of report-
ing of many validations was insufﬁcient to assess the
possibility of bias and generalizability of validity esti-
mates across the GPRD.Finally,it is possible that validation
Table 2
Methods of validation and median percentage of cases conﬁrmed using each method
Validation method
n validations
carried out
Percentage of cases
conﬁrmed by validation
Median (Range)
Internal
Manual review of computerized records
or diagnostic algorithm
31 86.2 (33–100)
Sensitivity analysis 23 n/a
External
Comparison of rates 143 n/a
Additional information from GP 160 88.6 (24–100)
Questionnaire to GP only 43 91.7 (26–93)
Questionnaire and record request to GP 39 90.0 (41–100)
Record request to GP only 78 82.7 (24–100)
Total 357 88.6 (24–100)
It was a requirement for inclusion in our review for each study (with the exception of comparison of rates and sensitivity analyses) to provide a numerical estimate of the proportion
of cases conﬁrmed.
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published and that this publication bias could have
affected our results.
The most robust method of validation may be to
request additional information from the GP, since this
methodusesinformationexternaltothedatabasetoverify
disease status of individual cases. Most such validations
were restricted to establishing the proportion of cases
with speciﬁc diagnostic codes that were conﬁrmed by
medical record review or responses to questionnaires,
thus providing an estimate of the PPV of that set of codes
(Figure 2). Although a useful measure, PPV varies with
disease prevalence,so use of historical validations may not
be justiﬁed if disease incidence has changed over time.
Information for cases alone does not allow calculation
of sensitivity (the proportion of true cases correctly iden-
tiﬁed in the GPRD data), speciﬁcity (the proportion of
individuals without the disease identiﬁed as such in the
database),or negative predictive value.Even if PPV is high,
other measures of validity could be low.These other mea-
sures require additional sampling of individuals without
the diagnostic codes of interest (Figure 2). In most valida-
tions, the sensitivity, speciﬁcity and negative predictive
value are not assessed, and this may be partly explained
by the fact that for rare diseases, sampling from the vast
number of individuals without the code of interest is par-
ticularly daunting.A handful of publications have success-
fully investigated sensitivity and speciﬁcity of diagnoses,
demonstrating high validity for certain GPRD diagnoses
[20,21].Forexample,Nazareth[8]estimatedsensitivityand
PPV of schizophrenia and psychosis diagnoses.
As described in Table 4, the proportion of identiﬁed
cases that underwent validation was highly variable.
Where this proportion is low, the precision of the validity
estimate is reduced; most studies did not report conﬁ-
dence intervals around the PPV.Where only a proportion
of total cases have been validated, it would be useful to
compare those cases found to be valid with all other cases
in terms of age,sex and other descriptive variables to look
for systematic differences between them. One reason for
small sample sizes in many validations is the high ﬁnancial
cost of record retrieval from GPs (currently averaging £70
per single set of notes).
Some GPRD practices do not participate in research
studies, raising the question of generalizability of valida-
tion ﬁndings.For example,in a study by Van Staa [13],719
practices contributed to the database during the study
period but only 295 (41%) were known to provide addi-
tional information. Thus, even if compliance in providing
records is high, the observed PPV may be applicable only
to cases from a subgroup of practices. Practices who do
participateinvalidationstudiesmayonlysendinformation
for certain cases, e.g.refusing to copy very large case ﬁles
[22];thismayresultinselectionbias.Manypublicationsdid
not report response rates clearly (with a complete lack of
reporting in 16% of validations), making it impossible to
assess whether selection bias could have affected their
validation results.Where practices did respond to requests
there were three possible outcomes: (i) notes were un-
available due to patient transfer or death, (ii) notes were
returned with incomplete and/or inconclusive details of
disease diagnosis, (iii) notes were returned with sufﬁcient
detail to verify the diagnosis. Since nonresponse, inad-
equate notes and exclusion because of patient death/
transfer could bias assessment of validity in different ways,
it would be useful to report them separately.
GiventhehighcostofrecordretrievalandGPquestion-
naires,manual review of the computerized records is cost
effective but is also time consuming and takes away much
of the advantage of having automated data.Less than half
of the validations using this method speciﬁed the criteria
used to determine ‘true’ cases. Without prespeciﬁed case
criteria, there is scope for bias arising from judgements
by individual physicians, which may vary over time and
between physicians.Furthermore,recording of symptoms,
results of diagnostic procedures and feedback from
Gold standard diagnosis
Disease No  disease Total 
GPRD
database
Disease A
(true cases correctly
identified in GPRD)
B
(non-cases wrongly coded 
as cases in GPRD)
A + B
No disease C 
(true cases not identified 
in GPRD)
D 
(true non-cases correctly
identified in GPRD)
C + D
Total A + CB  + DA  + B + C + D
Figure 2
Measures of validity of categorical data.Sensitivity:A/(A+C);speciﬁcity:D/(B+D);positive predictive value:A/(A+B);negative predictive value:D/(C+D)
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records,thereby limiting the usefulness of this approach.
Many investigators develop internal diagnostic algo-
rithms to identify cases, but few use these to validate
speciﬁc diagnostic codes (e.g. a medical code for acute
myocardial infarction was validated by the presence of
supportive evidence, e.g. codes for chest pain, ﬁbrinolytic
therapy,coronaryintervention,troponintestresultsorhos-
pitalization [23]).This method is quick and incurs no extra
cost,so could be used more widely to validate diseases for
which speciﬁc treatments are given universally. However,
use of such algorithms may exclude less severe cases that
do not require treatment, and the inclusion of test results
in these algorithms is problematic since not all test results
are recorded in the GPRD.
Comparison of rates gives a quick indication of the
validity of the GPRD without the effort of individual case
review. These comparisons do not validate individual
cases or provide a measurable estimate of validity.Where
prevalence rates are being compared, the GPRD may
have a lower prevalence because GPs are not required
to code prevalent conditions in each consultation [18].
Although results are reassuring for descriptive purposes,
comparable rates of disease cannot identify potential
balanced misclassiﬁcations between different diagnoses
(i.e. the situation sometimes seen in death certiﬁcation
where the loss of deaths from cause A because of mis-
classiﬁcation is balanced by the inclusion of people dying
of cause B but misclassiﬁed to cause A). Reliance on this
method to establish the validity of a diagnosis in the
GPRD should be approached with caution and is not
appropriate in analytic studies where individual validity
is required. Similarly, sensitivity analysis is not a true
validation of the data but does give an indication of
the quality of diagnoses.
Most studies carried out using GPRD data are nested
case–control studies. When conducting such a study, it is
important to apply the same inclusion and exclusion crite-
riatocasesandcontrols.However,validationstudieswhich
focus solely on cases may produce more detailed criteria
for cases than for controls. For example, Garcia Rodriguez
[24]investigatedtherelationbetweenexposuretononste-
roidal anti-inﬂammatory drugs and acute liver injury.The
investigatorsretrievedmedicalrecordsofacuteliverinjury
cases to verify their computerized diagnosis and excluded
16 of 166 potential cases (10%) from further analyses due
to alcoholism. No further details on alcohol consumption
by controls were retrieved, which may have led to bias.
Validating a sample of noncases should ensure that
control patients are subject to the same criteria as cases,
although this would increase the ﬁnancial cost of the
research.
Analternativeapproachisthemethodthatwerecently
applied to validate GPRD diagnoses of RA [22]. We used
external medical records to validate RA diagnoses,but did
notsimplyassesstheoverallPPVofanRAcode.Instead,we
identiﬁed characteristics in the computerized records of
RA-coded patients that were associated with a valid diag-
nosis (e.g.speciﬁc prescriptions),and carried out multivari-
able analyses of these characteristics (using a valid RA
diagnosis as the outcome) to develop a data-derived diag-
nostic algorithm of characteristics that could be used to
identifyvalidcasesinthedatabase[25].Thismethodcould
be adapted to develop algorithms for a wide range of
GPRD diagnoses.
Although considerable effort is often made to validate
cases, the lack of detailed description of validation
methods hinders interpretation of results. In some publi-
cations, lack of reporting was due to space constraints,
which could be overcome by providing the relevant data
asawebsupplement.Itisalsohelpfultomakeaccessiblea
table of the medical OXMIS and Read codes used for diag-
nosis (or the mapping of these codes to speciﬁc ICD
codes), so that others studying the disease can replicate
case identiﬁcation criteria. Figure 3 summarizes other
information that could be made available to aid inter-
pretation of validations.
Conclusion
The GPRD is an enormously powerful tool for the study
of morbidity as recorded in primary care, but the quality
of research using the data depends on the validity of
the computerized information. It is therefore important
for studies to perform some form of validation.At present,
robust validations requesting additional information from
GPs are limited in size due to costs,and their generalizabil-
ity is compromised by nonparticipation of many practices.
Careful use of internal diagnostic algorithms overcomes
these concerns,and is a cost-effective method of identify-
ing valid individual cases.
In future, it is likely that results from external clinical
investigations and letters from specialists will be better
captured in electronic records. These advances, along
with the introduction of the Quality of Outcomes
Framework, will greatly strengthen validations and are
likely to improve the quality of the data (with fewer data
entry errors and improved completeness). Work is also
underwaytoextendtheuseofGPRDasabasisforrandom-
ized trials and as a sampling frame to obtain genetic data.
Linkage of GPRD with other healthcare databases (e.g.
linkage to Hospital Episode Statistics), disease registers
anddeathcertiﬁcateswillallowresearcherstocorroborate
diagnoses made in hospital without the need to request
medical records, and linkage to cancer registry data and
the national audit of myocardial infarction (MINAP) will
provide further opportunities. However, use of such link-
ages raises questions of how to resolve discordant or
missing diagnoses in the two data sources.We hope that
this study generates further debate about how best to
assess the quality of the database and that this will further
E.Herrett et al.
12 / 69:1 / Br J Clin Pharmacolenhance the reputation and the strength of the GPRD for
use in research.
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